PURPOSE: The aim of this pilot study was to test whether mathematical parameters of the vascular morphology of choroidal neovascularization (CNV) can be used as biomarkers and to investigate how these parameters change during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Treatment-naive CNV in exudative age-related macular degeneration (AMD) was diagnosed in 28 patients. OCT-angiography (OCT-A) (Avanti/FA Optovue) performed before and after anti-VEGF therapy. The OCT-A data sets were exported to an external image processing program and vessel skeletonization was accomplished by means of edge detection. Based on this technique the total vessel length, the number of segments and the fractal dimension (FD) of the CNV were calculated before and after therapy. The results were compared with other clinical parameters such as VA and central retinal thickness (RT). RESULTS: The total vessel length of the CNV was significantly reduced by anti-VEGF-therapy (mean value 652 pixels vs. 397 pixels; p < 0.0001), as well as the number of individual vessel segments of the CNV (mean value 117 vs. 76; p < 0.0001). The FD of the CNV also decreased significant reduction during therapy (mean 1.23 vs. 1.16, p < 0.0001). The changes in these parameters during treatment corresponded with an increase in VA and a reduction in RT. CONCLUSION: This pilot study demonstrates that the vascular pattern of CNV in AMD can be visualized and described using mathematical parameters of OCT-A. The changes during therapy correlate significantly with established "activity" parameters of CNV, so changes in these parameters (especially FD) may represent additional CNV "activity" biomarkers.
PURPOSE: The aim of this pilot study was to test whether mathematical parameters of the vascular morphology of choroidal neovascularization (CNV) can be used as biomarkers and to investigate how these parameters change during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Treatment-naive CNV in exudative age-related macular degeneration (AMD) was diagnosed in 28 patients. OCT-angiography (OCT-A) (Avanti/FA Optovue) performed before and after anti-VEGF therapy. The OCT-A data sets were exported to an external image processing program and vessel skeletonization was accomplished by means of edge detection. Based on this technique the total vessel length, the number of segments and the fractal dimension (FD) of the CNV were calculated before and after therapy. The results were compared with other clinical parameters such as VA and central retinal thickness (RT). RESULTS: The total vessel length of the CNV was significantly reduced by anti-VEGF-therapy (mean value 652 pixels vs. 397 pixels; p < 0.0001), as well as the number of individual vessel segments of the CNV (mean value 117 vs. 76; p < 0.0001). The FD of the CNV also decreased significant reduction during therapy (mean 1.23 vs. 1.16, p < 0.0001). The changes in these parameters during treatment corresponded with an increase in VA and a reduction in RT. CONCLUSION: This pilot study demonstrates that the vascular pattern of CNV in AMD can be visualized and described using mathematical parameters of OCT-A. The changes during therapy correlate significantly with established "activity" parameters of CNV, so changes in these parameters (especially FD) may represent additional CNV "activity" biomarkers.
Authors: Eliana Costanzo; Alexandra Miere; Giuseppe Querques; Vittorio Capuano; Camille Jung; Eric H Souied Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Neal V Palejwala; Yali Jia; Simon S Gao; Liang Liu; Christina J Flaxel; Thomas S Hwang; Andreas K Lauer; David J Wilson; David Huang; Steven T Bailey Journal: Retina Date: 2015-11 Impact factor: 4.256
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Laura Kuehlewein; Mayank Bansal; Tamara L Lenis; Nicholas A Iafe; SriniVas R Sadda; Marco A Bonini Filho; Talisa E De Carlo; Nadia K Waheed; Jay S Duker; David Sarraf Journal: Am J Ophthalmol Date: 2015-07-09 Impact factor: 5.258
Authors: Gabriel Coscas; Marco Lupidi; Florence Coscas; Catherine Français; Carlo Cagini; Eric H Souied Journal: Ophthalmic Res Date: 2015-07-17 Impact factor: 2.892
Authors: Henrik Faatz; Kai Rothaus; Martin Ziegler; Marius Book; Claudia Lommatzsch; Georg Spital; Matthias Gutfleisch; Daniel Pauleikhoff; Albrecht Lommatzsch Journal: Clin Ophthalmol Date: 2020-10-09
Authors: Henrik Faatz; Kai Rothaus; Martin Ziegler; Marius Book; Georg Spital; Britta Heimes-Bussmann; Daniel Pauleikhoff; Albrecht Lommatzsch Journal: Int Ophthalmol Date: 2022-01-13 Impact factor: 2.029
Authors: Tristan T Hormel; Yali Jia; Yifan Jian; Thomas S Hwang; Steven T Bailey; Mark E Pennesi; David J Wilson; John C Morrison; David Huang Journal: Prog Retin Eye Res Date: 2020-07-24 Impact factor: 21.198
Authors: Henrik Faatz; Marie-Louise Farecki; Kai Rothaus; Matthias Gutfleisch; Daniel Pauleikhoff; Albrecht Lommatzsch Journal: BMJ Open Ophthalmol Date: 2019-12-10